---
document_datetime: 2025-12-02 05:49:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/edarbi.html
document_name: edarbi.html
version: success
processing_time: 0.1212417
conversion_datetime: 2025-12-23 21:18:51.623878
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Edarbi

[RSS](/en/individual-human-medicine.xml/66591)

##### Authorised

This medicine is authorised for use in the European Union

azilsartan medoxomil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Edarbi](#news-on)
- [More information on Edarbi](#more-information-on-edarbi-731)
- [More information on Edarbi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Edarbi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Edarbi.

Expand section

Collapse section

## What is Edarbi?

Edarbi is a medicine that contains the active substance azilsartan medoxomil. It is available as tablets (20, 40 and 80 mg).

## What is Edarbi used for?

Edarbi is used in adults who have essential hypertension (high blood pressure). 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Edarbi used?

Edarbi is taken by mouth and the usual recommended dose is 40 mg once a day. If the blood pressure is not sufficiently controlled, the dose can be increased to 80 mg, or another medicine for hypertension, such as chlortalidone or hydrochlorothiazide, can be added.

## How does Edarbi work?

The active substance in Edarbi, azilsartan medoxomil, is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, azilsartan medoxomil stops the hormone from having an effect, therefore allowing the blood vessels to widen. This allows the blood pressure to fall towards normal, thus reducing the risks associated with high blood pressure, such as having a stroke.

## How has Edarbi been studied?

Eight main studies involving over 6,000 patients with essential hypertension were carried out with Edarbi.

Five studies investigated the effects of Edarbi taken alone, comparing it with placebo (a dummy treatment) or with other antihypertensive medicines (ramipril, valsartan and olmesartan medoxomil). The patients in these studies had mild to moderate hypertension.

Three studies investigated the effects of Edarbi in combination with other antihypertensive medicines (chlortalidone, amlodipine, and hydrochlorothiazide). The patients in the combination studies had moderate to severe hypertension.

The studies lasted between six and 56 weeks and the main measure of effectiveness was the change in the systolic blood pressure (blood pressure when the heart is contracting).

## What benefit has Edarbi shown during the studies?

Edarbi on its own was more effective than placebo. In the two studies with Edarbi taken alone compared with placebo, patients had an average fall in systolic blood pressure of about 13.5 mmHg on Edarbi 40 mg and a fall of about 14.5 mmHg on Edarbi 80 mg after 6 weeks. This compares with a fall of 0.3 to 1.4 mmHg in the patients taking placebo.

When Edarbi alone was compared with other medicines, 80 mg of Edarbi was more effective in lowering blood pressure than the highest approved dose of valsartan (320 mg) and olmesartan medoxomil (40 mg). Edarbi 40 and 80 mg was also more effective than ramipril (10 mg).

The studies also showed that Edarbi, when taken in combination with other medicines, can produce additional decreases in blood pressure compared with when these medicines are taken without Edarbi.

## What is the risk associated with Edarbi?

Side effects with Edarbi are generally mild or moderate, with the most common side effect being dizziness. For the full list of all side effects reported with Edarbi, see the package leaflet.

Edarbi must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is also not recommended. Edarbi must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with diabetes or in patients with moderate or severe kidney impairment. For the full list of restrictions, see the package leaflet.

## Why has Edarbi been approved?

The CHMP concluded that Edarbi belongs to an established class of medicines in the treatment of hypertension and its risks are similar to others within this class. The Committee decided that the benefits of Edarbi are greater than its risks in patients with essential hypertension and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Edarbi?

A risk management plan has been developed to ensure that Edarbi is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Edarbi, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Edarbi

The European Commission granted a marketing authorisation valid throughout the European Union for Edarbi on 7 December 2011.

For more information about treatment with Edarbi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Edarbi : EPAR - Summary for the public

Reference Number: EMA/807101/2011

English (EN) (77.72 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 13/07/2015

[View](/en/documents/overview/edarbi-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-581)

български (BG) (103.92 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/bg/documents/overview/edarbi-epar-summary-public_bg.pdf)

español (ES) (99.07 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/es/documents/overview/edarbi-epar-summary-public_es.pdf)

čeština (CS) (125.37 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/cs/documents/overview/edarbi-epar-summary-public_cs.pdf)

dansk (DA) (76.96 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/da/documents/overview/edarbi-epar-summary-public_da.pdf)

Deutsch (DE) (100.49 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/de/documents/overview/edarbi-epar-summary-public_de.pdf)

eesti keel (ET) (77.92 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/et/documents/overview/edarbi-epar-summary-public_et.pdf)

ελληνικά (EL) (127.83 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/el/documents/overview/edarbi-epar-summary-public_el.pdf)

français (FR) (101.04 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/fr/documents/overview/edarbi-epar-summary-public_fr.pdf)

hrvatski (HR) (97.53 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/hr/documents/overview/edarbi-epar-summary-public_hr.pdf)

italiano (IT) (98.78 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/it/documents/overview/edarbi-epar-summary-public_it.pdf)

latviešu valoda (LV) (122.49 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/lv/documents/overview/edarbi-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (123.28 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/lt/documents/overview/edarbi-epar-summary-public_lt.pdf)

magyar (HU) (98.93 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/hu/documents/overview/edarbi-epar-summary-public_hu.pdf)

Malti (MT) (104.52 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/mt/documents/overview/edarbi-epar-summary-public_mt.pdf)

Nederlands (NL) (76.95 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/nl/documents/overview/edarbi-epar-summary-public_nl.pdf)

polski (PL) (103.05 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/pl/documents/overview/edarbi-epar-summary-public_pl.pdf)

português (PT) (100.67 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/pt/documents/overview/edarbi-epar-summary-public_pt.pdf)

română (RO) (121.41 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/ro/documents/overview/edarbi-epar-summary-public_ro.pdf)

slovenčina (SK) (124.6 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/sk/documents/overview/edarbi-epar-summary-public_sk.pdf)

slovenščina (SL) (120.11 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/sl/documents/overview/edarbi-epar-summary-public_sl.pdf)

Suomi (FI) (98.37 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/fi/documents/overview/edarbi-epar-summary-public_fi.pdf)

svenska (SV) (76.21 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

13/07/2015

[View](/sv/documents/overview/edarbi-epar-summary-public_sv.pdf)

Edarbi : EPAR - Risk-management-plan summary

English (EN) (48.93 KB - PDF)

**First published:** 18/03/2020

[View](/en/documents/rmp-summary/edarbi-epar-risk-management-plan-summary_en.pdf)

## Product information

Edarbi : EPAR - Product Information

English (EN) (290.8 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 29/01/2025

[View](/en/documents/product-information/edarbi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-498)

български (BG) (390.22 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/bg/documents/product-information/edarbi-epar-product-information_bg.pdf)

español (ES) (341.36 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/es/documents/product-information/edarbi-epar-product-information_es.pdf)

čeština (CS) (385.54 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/cs/documents/product-information/edarbi-epar-product-information_cs.pdf)

dansk (DA) (317.8 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/da/documents/product-information/edarbi-epar-product-information_da.pdf)

Deutsch (DE) (378.99 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/de/documents/product-information/edarbi-epar-product-information_de.pdf)

eesti keel (ET) (308.9 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/et/documents/product-information/edarbi-epar-product-information_et.pdf)

ελληνικά (EL) (401.84 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/el/documents/product-information/edarbi-epar-product-information_el.pdf)

français (FR) (339.28 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/fr/documents/product-information/edarbi-epar-product-information_fr.pdf)

hrvatski (HR) (374.34 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/hr/documents/product-information/edarbi-epar-product-information_hr.pdf)

íslenska (IS) (332.43 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/is/documents/product-information/edarbi-epar-product-information_is.pdf)

italiano (IT) (327.6 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/it/documents/product-information/edarbi-epar-product-information_it.pdf)

latviešu valoda (LV) (372.83 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/lv/documents/product-information/edarbi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (384.31 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/lt/documents/product-information/edarbi-epar-product-information_lt.pdf)

magyar (HU) (387.31 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/hu/documents/product-information/edarbi-epar-product-information_hu.pdf)

Malti (MT) (402.36 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/mt/documents/product-information/edarbi-epar-product-information_mt.pdf)

Nederlands (NL) (312.86 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/nl/documents/product-information/edarbi-epar-product-information_nl.pdf)

norsk (NO) (366.09 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/no/documents/product-information/edarbi-epar-product-information_no.pdf)

polski (PL) (393.41 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/pl/documents/product-information/edarbi-epar-product-information_pl.pdf)

português (PT) (317.76 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/pt/documents/product-information/edarbi-epar-product-information_pt.pdf)

română (RO) (380.29 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/ro/documents/product-information/edarbi-epar-product-information_ro.pdf)

slovenčina (SK) (388.06 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/sk/documents/product-information/edarbi-epar-product-information_sk.pdf)

slovenščina (SL) (369.28 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/sl/documents/product-information/edarbi-epar-product-information_sl.pdf)

Suomi (FI) (313.53 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/fi/documents/product-information/edarbi-epar-product-information_fi.pdf)

svenska (SV) (308.98 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

29/01/2025

[View](/sv/documents/product-information/edarbi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246998 29/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Edarbi : EPAR - All Authorised presentations

English (EN) (41.15 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 18/05/2018

[View](/en/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (42.4 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/bg/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_bg.pdf)

español (ES) (34.87 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/es/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.2 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/cs/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (32.59 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/da/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (33.9 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/de/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (32.33 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/et/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.97 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/el/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_el.pdf)

français (FR) (39.13 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/fr/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (50.03 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/hr/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.73 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/is/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/it/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.56 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/lv/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.84 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/lt/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.67 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/hu/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.85 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/mt/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.55 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/nl/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.76 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/no/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.85 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/pl/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_pl.pdf)

português (PT) (32.54 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/pt/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_pt.pdf)

română (RO) (32.85 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/ro/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.65 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/sk/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (33.16 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/sl/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (32.18 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/fi/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (33.39 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

18/05/2018

[View](/sv/documents/all-authorised-presentations/edarbi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Edarbi Active substance azilsartan medoxomil International non-proprietary name (INN) or common name azilsartan medoxomil Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA09

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Edarbi is indicated for the treatment of essential hypertension in adults.

## Authorisation details

EMA product number EMEA/H/C/002293 Marketing authorisation holder

Takeda Pharma A/S

Delta Park 45

Opinion adopted 22/09/2011 Marketing authorisation issued 07/12/2011 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Edarbi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.1 KB - PDF)

**First published:** 29/01/2025

[View](/en/documents/procedural-steps-after/edarbi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Edarbi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (142.1 KB - PDF)

**First published:** 11/06/2012

**Last updated:** 29/01/2025

[View](/en/documents/procedural-steps-after/edarbi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Edarbi-H-C-2293-A31-06 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendati...

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_en.pdf)

[Other languages (22)](#file-language-dropdown-224)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/edarbi-h-c-2293-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendati_sv.pdf)

Edarbi-H-C-2293-A31-06 : EPAR - Assessment Report - Article 31

Adopted

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/edarbi-h-c-2293-a31-06-epar-assessment-report-article-31_en.pdf)

Edarbi-H-C-2293-PSUV-08 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/538715/2013

English (EN) (73.07 KB - PDF)

**First published:** 02/07/2014

**Last updated:** 02/07/2014

[View](/en/documents/scientific-conclusion/edarbi-h-c-2293-psuv-08-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Edarbi : EPAR - Public assessment report

Adopted

English (EN) (847.48 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 15/12/2011

[View](/en/documents/assessment-report/edarbi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Edarbi

Adopted

Reference Number: EMA/CHMP/736839/2011

English (EN) (51.88 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 23/09/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-edarbi_en.pdf)

#### News on Edarbi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2013) 20/09/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

#### More information on Edarbi

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### More information on Edarbi

- [EMEA-000237-PIP01-08-M12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000237-pip01-08-m12)
- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Drug Utilization Study for azilsartan medoxomil in Germany - post-authorisation study](https://catalogues.ema.europa.eu/study/28627)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/01/2025

## Share this page

[Back to top](#main-content)